Iñigo de Miguel Beriain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Iñigo de Miguel Beriain has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Begoña Sanz
Department of Physiology, University of The Basque Country (UPV/EHU), 48940 Leioa, Spain
5 shared publications - Jon Rueda
Institute of Philosophy, Spanish National Research Council, Madrid, Spain
5 shared publications - Anibal Monasterio Astobiza
Department of Philosophy I, University of Granada, Granada, Spain
4 shared publications - Guillermo Lazcoz Moratinos
Biomedical Research Network on Rare Diseases Center (CIBERER-ISCIII), 28029 Madrid, Spain
4 shared publications Aliuska Duardo-Sánchez
IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
2 shared publications- Elena Atienza Macías
Universidad de Deusto
2 shared publications
Latest Publications
- 25 September 2026
- Published by Springer Nature in Erkenntnis
- p. 1-19
The Pitt–Johansson Paradox: Artificial Memories and the Value of Authenticity
- 25 September 2026
- Published by Springer Nature in Erkenntnis
- p. 1-19
The Pitt–Johansson Paradox: Artificial Memories and the Value of Authenticity
- Open Access
- 28 August 2026
- Published by Springer Nature in Neuroethics
- Vol. 19 (3) , 43
When Minds Merge: Neural Telepathy, Neurorights, and the Limits of Voluntary Privacy Waiver
The rapid advance of neurotechnology has produced a vibrant scholarly and legislative debate around neurorights — a proposed generation of human rights designed to protect mental privacy, cognitive liberty, mental integrity, and psychological continuity against the most threatening applications of neurotechnology. This article argues that the neurorights framework, while representing a genuine and important advance in the governance of neurotechnology, contains a structural blind spot: it was designed to protect individuals from non-consensual external interferences and is not well equipped to address scenarios in which individuals voluntarily choose to waive or dissolve their own mental privacy. To illuminate this limitation, the article focuses on a paradigm case made increasingly plausible by contemporary brain–computer interface (BCI) research: the scenario of a group of individuals who voluntarily interconnect their nervous systems into a form of technological "neural telepathy," sharing thoughts, emotions, and mental imagery continuously and without filter. We argue that such a scenario cannot be adequately governed by neurorights alone and demands a complementary framework of neuroduties — legally and morally binding obligations that flow from the embodied, relational nature of the human person and that constrain certain forms of radical voluntary self-transformation. We develop the philosophical foundations of this framework, engaging directly with liberal autonomy theory and with existing legal instruments, and identify three clusters of problems raised by consensual neural interconnection: (1) mental health and the preservation of the bounded self; (2) personal identity, individuation, and the attribution of moral and legal responsibility; and (3) the irreducible social and legal functions of privacy that transcend individual preference.
- 28 August 2026
- Published by Springer Nature in Neuroethics
- Vol. 19 (3) , 43
Open AccessWhen Minds Merge: Neural Telepathy, Neurorights, and the Limits of Voluntary Privacy Waiver
The rapid advance of neurotechnology has produced a vibrant scholarly and legislative debate around neurorights — a proposed generation of human rights designed to protect mental privacy, cognitive liberty, mental integrity, and psychological continuity against the most threatening applications of neurotechnology. This article argues that the neurorights framework, while representing a genuine and important advance in the governance of neurotechnology, contains a structural blind spot: it was designed to protect individuals from non-consensual external interferences and is not well equipped to address scenarios in which individuals voluntarily choose to waive or dissolve their own mental privacy. To illuminate this limitation, the article focuses on a paradigm case made increasingly plausible by contemporary brain–computer interface (BCI) research: the scenario of a group of individuals who voluntarily interconnect their nervous systems into a form of technological "neural telepathy," sharing thoughts, emotions, and mental imagery continuously and without filter. We argue that such a scenario cannot be adequately governed by neurorights alone and demands a complementary framework of neuroduties — legally and morally binding obligations that flow from the embodied, relational nature of the human person and that constrain certain forms of radical voluntary self-transformation. We develop the philosophical foundations of this framework, engaging directly with liberal autonomy theory and with existing legal instruments, and identify three clusters of problems raised by consensual neural interconnection: (1) mental health and the preservation of the bounded self; (2) personal identity, individuation, and the attribution of moral and legal responsibility; and (3) the irreducible social and legal functions of privacy that transcend individual preference.
- Open Access
- 29 July 2026
- Published by Springer Nature in Science and Engineering Ethics
What if I Want to be an Avatar: Moral and Legal Implications of Opting for a Life in the Metaverse
The rise of virtual worlds, collectively known as the Metaverse, compels a re-examination of longstanding debates concerning personal freedom, moral responsibility, and legal accountability. These immersive digital environments differ from prior communication technologies not merely in degree but in the phenomenological quality they produce: a pervasive sense of presence that blurs the boundary between the virtual and the physical. This article examines the ethical and legal challenges that arise when individuals choose to spend a substantial portion of their lives within such digital spaces. We introduce the concept of “Meta-Autonomy” as a theoretical framework for understanding personal agency in algorithmically mediated environments. We argue that existing accounts of autonomy — Kantian, procedural, and enactivist — each capture important dimensions of this challenge but face specific difficulties when confronted simultaneously with four structural properties of Metaverse environments: algorithmic mediation of choice architecture, radical fluidity of identity, networked and distributed causal agency, and the moral embeddedness of virtual experience. Meta-Autonomy is proposed as a framework that holds these four dimensions together and derives from their interaction both a set of diagnostic criteria for identifying autonomy deficits and a set of normative implications for regulation. We develop the thought experiment of “Plato’s Digital Cave” to illustrate the first-order/second-order autonomy distinction, and apply Meta-Autonomy’s four components systematically to specific legal questions — mens rea, legal personhood, distributed liability, virtual harm, and the regulation of Metaverse platforms under the GDPR, EU AI Act, and Digital Services Act. The article concludes by identifying concrete directions for future philosophical and legal research.
- 29 July 2026
- Published by Springer Nature in Science and Engineering Ethics
Open AccessWhat if I Want to be an Avatar: Moral and Legal Implications of Opting for a Life in the Metaverse
The rise of virtual worlds, collectively known as the Metaverse, compels a re-examination of longstanding debates concerning personal freedom, moral responsibility, and legal accountability. These immersive digital environments differ from prior communication technologies not merely in degree but in the phenomenological quality they produce: a pervasive sense of presence that blurs the boundary between the virtual and the physical. This article examines the ethical and legal challenges that arise when individuals choose to spend a substantial portion of their lives within such digital spaces. We introduce the concept of “Meta-Autonomy” as a theoretical framework for understanding personal agency in algorithmically mediated environments. We argue that existing accounts of autonomy — Kantian, procedural, and enactivist — each capture important dimensions of this challenge but face specific difficulties when confronted simultaneously with four structural properties of Metaverse environments: algorithmic mediation of choice architecture, radical fluidity of identity, networked and distributed causal agency, and the moral embeddedness of virtual experience. Meta-Autonomy is proposed as a framework that holds these four dimensions together and derives from their interaction both a set of diagnostic criteria for identifying autonomy deficits and a set of normative implications for regulation. We develop the thought experiment of “Plato’s Digital Cave” to illustrate the first-order/second-order autonomy distinction, and apply Meta-Autonomy’s four components systematically to specific legal questions — mens rea, legal personhood, distributed liability, virtual harm, and the regulation of Metaverse platforms under the GDPR, EU AI Act, and Digital Services Act. The article concludes by identifying concrete directions for future philosophical and legal research.
- Open Access
Regulating AI-Driven Triage: Fundamental Rights and Compliance Challenges in the European Union
Emergency triage is a critical healthcare action that could be improved through the use of artificial intelligence (AI) systems, as these have been shown to achieve accuracy rates of approximately 70–90% for LLMs and AUC values ranging from 0.75 to 0.95 for common AI models. However, these systems face challenges related to the rights and interests of the individuals involved. The European Union’s normative framework, including not only data protection regulations but also the AI Act and medical device regulations, imposes conditions on the use of AI, and these are analyzed here. Our conclusions reveal that Article 22 of the General Data Protection Regulation (GDPR) makes it difficult to justify the establishment of fully automated decision-making models for triage. That accountability obligations for implementers (Fundamental Rights Impact Assessments: FRIAs) and data controllers (data protection impact assessments: DPIAs) can contribute to better design of AI-based decision-making in triage. Furthermore, with regard to the information rights set out in the GDPR, these have been complemented by the right to an explanation under Art. 86 AI Act in the use of high-risk AI systems. Unfortunately, regulation relating to general-purpose AI models may create some gaps in this framework. The implementation of AI systems for automated decision-making in triage has the potential to improve medical care, but their use requires clarification of applicable regulations and safeguards for patients’ rights.
Open AccessRegulating AI-Driven Triage: Fundamental Rights and Compliance Challenges in the European Union
Emergency triage is a critical healthcare action that could be improved through the use of artificial intelligence (AI) systems, as these have been shown to achieve accuracy rates of approximately 70–90% for LLMs and AUC values ranging from 0.75 to 0.95 for common AI models. However, these systems face challenges related to the rights and interests of the individuals involved. The European Union’s normative framework, including not only data protection regulations but also the AI Act and medical device regulations, imposes conditions on the use of AI, and these are analyzed here. Our conclusions reveal that Article 22 of the General Data Protection Regulation (GDPR) makes it difficult to justify the establishment of fully automated decision-making models for triage. That accountability obligations for implementers (Fundamental Rights Impact Assessments: FRIAs) and data controllers (data protection impact assessments: DPIAs) can contribute to better design of AI-based decision-making in triage. Furthermore, with regard to the information rights set out in the GDPR, these have been complemented by the right to an explanation under Art. 86 AI Act in the use of high-risk AI systems. Unfortunately, regulation relating to general-purpose AI models may create some gaps in this framework. The implementation of AI systems for automated decision-making in triage has the potential to improve medical care, but their use requires clarification of applicable regulations and safeguards for patients’ rights.
- Open Access
- 10 June 2025
- Published by EHU Press in Revista de Derecho y Genoma Humano. Genética, Biotecnología y Medicina Avanzada
El nuevo reglamento europeo relativo al espacio europeo de datos de salud: su impacto en la gobernanza del dato y su uso ético y seguro
En las siguientes líneas se examina la Estrategia Europea de Datos, cuyo objetivo es la creación de un mercado único de datos en la Unión Europea. Se analizan los principales instrumentos normativos, como la Ley de Gobernanza de Datos y la Ley de Datos, así como el desarrollo de espacios sectoriales de datos. Además, se estudian iniciativas clave, como el Data Spaces Support Centre y el Espacio Europeo de Datos de salud, con especial atención a su impacto en la gobernanza de datos y la interoperabilidad en el ámbito digital europeo.
- 10 June 2025
- Published by EHU Press in Revista de Derecho y Genoma Humano. Genética, Biotecnología y Medicina Avanzada
Open AccessEl nuevo reglamento europeo relativo al espacio europeo de datos de salud: su impacto en la gobernanza del dato y su uso ético y seguro
En las siguientes líneas se examina la Estrategia Europea de Datos, cuyo objetivo es la creación de un mercado único de datos en la Unión Europea. Se analizan los principales instrumentos normativos, como la Ley de Gobernanza de Datos y la Ley de Datos, así como el desarrollo de espacios sectoriales de datos. Además, se estudian iniciativas clave, como el Data Spaces Support Centre y el Espacio Europeo de Datos de salud, con especial atención a su impacto en la gobernanza de datos y la interoperabilidad en el ámbito digital europeo.
Is more data always better? On alternative policies to mitigate bias in Artificial Intelligence health systems
The development and implementation of Artificial Intelligence (AI) health systems represent a great power that comes with great responsibility. Their capacity to improve and transform healthcare involves inevitable risks. A major risk in this regard is the propagation of bias throughout the life cycle of the AI system, leading to harmful or discriminatory outcomes. This paper argues that the European medical device regulations may prove inadequate to address this — not only technical but also social challenge. With the advent of new regulatory remedies, it seems that the European policymakers also want to reinforce the current medical device legal framework. In this paper, we analyse different policies to mitigate bias in AI health systems included in the Artificial Intelligence Act and in the proposed European Health Data Space. As we shall see, the different remedies based on processing sensitive data for such purpose devised by the European policymakers may have very different effects both on privacy and on protection against discrimination. We find the focus on mitigation during the pre‐commercialisation stages rather weak, and believe that bias control once the system has been implemented in the real world would have merited greater ambition.
Is more data always better? On alternative policies to mitigate bias in Artificial Intelligence health systems
The development and implementation of Artificial Intelligence (AI) health systems represent a great power that comes with great responsibility. Their capacity to improve and transform healthcare involves inevitable risks. A major risk in this regard is the propagation of bias throughout the life cycle of the AI system, leading to harmful or discriminatory outcomes. This paper argues that the European medical device regulations may prove inadequate to address this — not only technical but also social challenge. With the advent of new regulatory remedies, it seems that the European policymakers also want to reinforce the current medical device legal framework. In this paper, we analyse different policies to mitigate bias in AI health systems included in the Artificial Intelligence Act and in the proposed European Health Data Space. As we shall see, the different remedies based on processing sensitive data for such purpose devised by the European policymakers may have very different effects both on privacy and on protection against discrimination. We find the focus on mitigation during the pre‐commercialisation stages rather weak, and believe that bias control once the system has been implemented in the real world would have merited greater ambition.
- Open Access
- 1 October 2024
- Published by SAGE Publications in The CRISPR Journal
- Vol. 7 (5) , 220-226
Affordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative
Casgevy, the world’s first approved CRISPR-based cell therapy, has been priced at $2.2 million per patient. Although this hefty price tag was widely anticipated, the extremely high cost of this and other cell and gene therapies poses a major ethical issue in terms of equitable access and global health. In this Perspective, we argue that lowering the prices of future CRISPR therapies is an urgent ethical imperative. Although we focus on Casgevy as a case study, much of our analysis can be extrapolated to the controversies over affordable access to other gene and cell therapies. First, we explain why this first-of-its-kind CRISPR therapy might be so expensive. We then analyze the ethical issues of equity and global health of early CRISPR treatments. Next, we discuss potential solutions to lower the prices of CRISPR gene therapies. We conclude that the approval of CRISPR transforms our obligations of justice and compels us to bring future gene therapies to the maximum possible number of patients with serious genetic diseases at affordable prices.
- 1 October 2024
- Published by SAGE Publications in The CRISPR Journal
- Vol. 7 (5) , 220-226
Open AccessAffordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative
Casgevy, the world’s first approved CRISPR-based cell therapy, has been priced at $2.2 million per patient. Although this hefty price tag was widely anticipated, the extremely high cost of this and other cell and gene therapies poses a major ethical issue in terms of equitable access and global health. In this Perspective, we argue that lowering the prices of future CRISPR therapies is an urgent ethical imperative. Although we focus on Casgevy as a case study, much of our analysis can be extrapolated to the controversies over affordable access to other gene and cell therapies. First, we explain why this first-of-its-kind CRISPR therapy might be so expensive. We then analyze the ethical issues of equity and global health of early CRISPR treatments. Next, we discuss potential solutions to lower the prices of CRISPR gene therapies. We conclude that the approval of CRISPR transforms our obligations of justice and compels us to bring future gene therapies to the maximum possible number of patients with serious genetic diseases at affordable prices.
- 14 May 2024
- Published by Springer Nature
- p. 147-164
Use of AI Tools for Forensic Purposes: Ethical and Legal Considerations from an EU Perspective
- 14 May 2024
- Published by Springer Nature
- p. 147-164
Use of AI Tools for Forensic Purposes: Ethical and Legal Considerations from an EU Perspective
- Open Access
- 2 January 2024
- Published by Springer Nature in EMBO Reports
- Vol. 25 (2) , 467-470
Re-defining the human embryo
A universal legal definition of an embryo as a basis for regulation would create legal certainty for scientists and benefit international research cooperation. [Image: see text]
- 2 January 2024
- Published by Springer Nature in EMBO Reports
- Vol. 25 (2) , 467-470
Open AccessRe-defining the human embryo
A universal legal definition of an embryo as a basis for regulation would create legal certainty for scientists and benefit international research cooperation. [Image: see text]